Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EMD 273066 plus low-dose cyclophosphamide vs best supportive care in extensive-disease small cell lung cancer after response to platinum-based therapy
2006-004566-13Phase 2Completed
- Sponsor
- Merck KGaA
- Start
- Jul 2007
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Cytokines & Interferons → Recombinant Proteins and Enzymes, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in small cell lung cancer (SCLC) comparing EMD 273066 plus low-dose cyclophosphamide with Best supportive care alone (2 arms). Primary endpoints: Overall survival at 12 months, Overall survival at 18 months and 1 more. Started Jul 2007; status: completed.
02
Drugs
tucotuzumab celmoleukin
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on 2006-004566-13.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-004566-13.